. FDA Pauses Approval of Novavax COVID-19 Vaccine
Dr. Sara Brenner, the FDA's Principal Deputy Commissioner, has halted the approval process for Novavax’s COVID-19 vaccine, requesting additional data despite the agency’s principle of insulating scientific reviews from political influence. This unusual intervention coincides with the dismissal of top vaccine reviewer Dr. Peter Marks and administrative leave for his deputy. Novavax maintains it has met all FDA information requirements, and full approval is crucial for a $175 million partnership deal with Sanofi set to commence in the 2025-2026 virus season.
No comments:
Post a Comment